Drugs / FMP012
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02174978 | Aug 2014 → Jun 2015 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT01540474 | Feb → Oct 2012 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMP012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02174978 ↗ |
| Modality | Vaccine | “Biological/vaccine; E-coli expressed malaria antigen FMP012” NCT01540474 ↗ |
| Route | Intramuscular | “Administered Intramuscularly” NCT01540474 ↗ |